HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on ...

The boards of directors of Hookipa Pharma (HOOK) and Poolbeg Pharma announced that they have entered into non-binding discussions for an all-share acquisition by Hookipa of Poolbeg to create a ...

In a challenging year for biotech firms, Hookipa Pharma Inc (NASDAQ:HOOK). shares have tumbled to a 52-week low, touching down at $1.71. According to InvestingPro analysis, the company ...

After announcing acquisition plans at the beginning of 2025, immunotherapeutics biotech Hookipa Pharma has decided not to buy rare disease company Poolbeg Pharma. Jan. 2, Hookipa inked a ...

The UK's Poolbeg Pharma has disclosed that it is in talks over a possible combination with Hookipa, an Austrian biotech that is listed on the Nasdaq. The all-share merger – which, if completed ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Hookipa Pharma (HOOK – Research Report) on February 28 and set a price target of $2.00. The company’s shares closed yesterday at ...

Short interest in HOOKIPA Pharma Inc (NASDAQ:HOOK) decreased during the last reporting period, falling from 145.87K to 91.50K. This put 1.18% of the company's publicly available shares short.

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing cancer immunotherapies that harness arenaviruses to induce robust and durable antigen-specific CD8 + T cells to kill ...

HOOKIPA Pharma Inc. announced that it will not proceed with a planned all-share acquisition of Poolbeg Pharma plc, as discussed in previous communications. This decision follows non-binding ...

HOOKIPA Pharma (HOOK) announced that enrollment is complete in the Phase 1b clinical trial evaluating HB-500 for the treatment of HIV, with 30 participants enrolled across five sites in the United ...